Trial Profile
A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Apr 2024
Price :
$35
*
At a glance
- Drugs Parsaclisib (Primary)
- Indications Autoimmune haemolytic anaemia
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Incyte Corporation
- 08 Apr 2024 Status changed from active, no longer recruiting to completed.
- 23 Oct 2023 Planned End Date changed from 8 Sep 2023 to 29 Mar 2024.
- 17 Jun 2022 Results assessing long-term efficacy and safety of parsaclisib for the treatment of autoimmune hemolytic anemia, presented at the 27th Congress of the European Haematology Association.